Drug Discovery World

SEPTEMBER 29, 2022

Many companies have several projects ongoing simultaneously, which can limit internal resources (space, lab equipment, personnel) and delay progress. The company has the resources to complete the project in-house or it could outsource it to CROs. protein-protein or small molecule-target interactions).

Small Molecule 130

Small Molecule Assay Development DNA Biochemical Assays 130

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. It has a vibrant community of life-science companies, from global pharma to smaller start-ups.

Drugs 190

Drugs Science Therapies Targeted Protein Degradation 190

Drug Discovery World

JANUARY 3, 2023

Matthew Clark , CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Artificial intelligence. Wu Z, et al.

DNA 130

DNA Targeted Protein Degradation Small Molecule Pharma Companies 130

Vial

FEBRUARY 19, 2024

Can you elaborate on how the platform allows your company to tailor therapy? We can link small molecule drugs to a payload that would enter in the cell and kill it. We have the capability of different types of targets, whether small molecules or antibodies. Ahmed Hamby: We also have a very cool modification.

Small Molecule 52

Small Molecule Therapies Treatment Science 52